Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Merck
US Department of Justice
Queensland Health
Moodys
Fuji
Harvard Business School
Federal Trade Commission

Generated: September 20, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLONIDINE

« Back to Dashboard

Clinical Trials for Clonidine

Trial ID Title Status Sponsor Phase Summary
NCT00000800 Methadone Effects on Zidovudine (ZDV, AZT) Disposition Completed Glaxo Wellcome Phase 1 To determine whether methadone maintenance alters the pharmacokinetics of zidovudine (AZT). To determine whether any such effect of methadone on disposition of AZT is time dependent and whether a metabolic interaction between AZT and methadone exists. Injection drug users represent an increasing proportion of HIV-infected persons. Since daily methadone maintenance is the major chemical treatment for injection drug abuse, it is important to determine the impact of methadone on AZT absorption, distribution, and elimination.
NCT00000800 Methadone Effects on Zidovudine (ZDV, AZT) Disposition Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 To determine whether methadone maintenance alters the pharmacokinetics of zidovudine (AZT). To determine whether any such effect of methadone on disposition of AZT is time dependent and whether a metabolic interaction between AZT and methadone exists. Injection drug users represent an increasing proportion of HIV-infected persons. Since daily methadone maintenance is the major chemical treatment for injection drug abuse, it is important to determine the impact of methadone on AZT absorption, distribution, and elimination.
NCT00003771 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the risk of breast cancer recurrence in women with previous early stage breast cancer who are receiving hormone replacement therapy for menopause symptoms.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Clonidine

Condition Name

Condition Name for Clonidine
Intervention Trials
Pain 14
Hypertension 11
Postoperative Pain 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Clonidine
Intervention Trials
Pain, Postoperative 23
Hypertension 10
Syndrome 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Clonidine

Trials by Country

Trials by Country for Clonidine
Location Trials
United States 210
France 13
Canada 12
Brazil 11
Egypt 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Clonidine
Location Trials
New York 16
Maryland 15
Texas 14
Ohio 13
California 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Clonidine

Clinical Trial Phase

Clinical Trial Phase for Clonidine
Clinical Trial Phase Trials
Phase 4 67
Phase 3 32
Phase 2/Phase 3 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Clonidine
Clinical Trial Phase Trials
Completed 117
Recruiting 41
Unknown status 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Clonidine

Sponsor Name

Sponsor Name for Clonidine
Sponsor Trials
National Institute on Drug Abuse (NIDA) 10
Cairo University 5
Assiut University 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Clonidine
Sponsor Trials
Other 278
NIH 25
Industry 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Federal Trade Commission
Deloitte
Fuji
Cipla
Harvard Business School
Boehringer Ingelheim
Daiichi Sankyo
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.